Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines
Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, Gueiros LA, Majorana A, Nair RG, Ranna V, Tissing WJE, Vaddi A, Lubart R, Migliorati CA, Lalla RV, Cheng KKF, Elad S, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 269 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- University of Rochester
- Universidad u hospital
- Medical Center, University of Rochester
Según 2 financiadores declarados.
Publicación
- Publicado
- 2019-07-08 · Support Care Cancer · vol. 27 · número 10 · págs. 3969–3983
- Editorial
- Springer Science+Business Media
- Citado
- 367 citas · más que el 99% de estudios similares · 10.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 85 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Oral health in cancer treatment · Laser Applications in Dentistry and Medicine · Oral Health Pathology and Treatment
- Palabras clave
- low-level laser therapy, oral mucositis, cancer patients, laser therapy, phototherapy, hematopoietic stem cell transplantation, head and neck radiotherapy, chemotherapy-induced mucositis, mucositis prevention, oral pain
- MeSH
- humans, neoplasms, stomatitis, clinical protocols, male, mucositis, practice guidelines as topic, low-level light therapy
17 autores
- Yehuda Zadik🇮🇱 · autor de correspondenciaHebrew University of Jerusalem; Israel Defense Forces Medical Corps
- Praveen Ravindra Arany🇺🇸 · autor de correspondenciaUniversity at Buffalo, State University of New York
- Eduardo Rodrigues Fregnani🇧🇷Hospital Sírio-Libanês
- Paolo Bossi🇮🇹Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; University of Brescia
- Héliton Spíndola Antunes🇧🇷Instituto Nacional de Câncer - INCA
- René‐Jean Bensadoun🇫🇷Centre de Haute Energie
- Luiz Alcino Gueiros🇧🇷Universidade Federal de Pernambuco
- Alessandra Majorana🇮🇹University of Brescia
- RAJ G. NAIR🇦🇺Griffith University; Gold Coast Hospital
- Vinisha Ranna🇺🇸Mount Sinai Hospital; Icahn School of Medicine at Mount Sinai
- Wim J. E. Tissing🇳🇱University Medical Center Groningen; Beatrix Kinderziekenhuis
- Anusha Vaddi🇺🇸University of Rochester Medicine; University of Rochester
- Rachel Lubart🇮🇱Bar-Ilan University
- Cesar Augusto Migliorati🇺🇸University of Florida
- Rajesh V. Lalla🇺🇸UConn Health
- Karis Kin Fong Cheng🇸🇬National University of Singapore
- Sharon Elad🇺🇸University of Rochester Medicine; University of Rochester
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To systematically review the literature and update the evidence-based clinical practice guidelines for the use of photobiomodulation (PBM), such as laser and other light therapies, for the prevention and/or treatment of oral mucositis (OM).
Methods
A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using PubMed and Web of Science. We followed the MASCC methods for systematic review and guidelines development. The rigorously evaluated evidence for each intervention, in each cancer treatment setting, was assigned a level-of-evidence (LoE). Based on the LoE, one of the following guidelines was determined: Recommendation, Suggestion, or No Guideline Possible.
Results
Recommendations are made for the prevention of OM and related pain with PBM therapy in cancer patients treated with one of the following modalities: hematopoietic stem cell transplantation, head and neck (H&N) radiotherapy (without chemotherapy), and H&N radiotherapy with chemotherapy. For each of these modalities, we recommend 1-2 clinically effective protocols; the clinician should adhere to all parameters of the protocol selected. Due to inadequate evidence, currently, No Guideline Possible for treatment of established OM or for management of chemotherapy-related OM. The reported clinical settings were extremely variable, limiting data integration.
Conclusions
The evidence supports the use of specific settings of PBM therapy for the prevention of OM in specific patient populations. Under these circumstances, PBM is recommended for the prevention of OM. The guidelines are subject to continuous update based on new published data.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.